Kidney Cell Cycle Arrest and Cardiac Biomarkers and Acute Kidney Injury Following Angiography: The Prevention of Serious Adverse Events Following Angiography (PRESERVE) Study

Raghavan Murugan, Monique Y Boudreaux-Kelly, John A Kellum, Paul M Palevsky, Steven Weisbord, Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON) Study Investigators, Raghavan Murugan, Monique Y Boudreaux-Kelly, John A Kellum, Paul M Palevsky, Steven Weisbord, Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON) Study Investigators

Abstract

Rationale & objective: Recent studies in patients with chronic kidney disease (CKD) indicate that most cases of contrast-associated acute kidney injury (CA-AKI) are mild and are not associated with elevation in kidney injury biomarkers. We used highly sensitive kidney cell cycle arrest and cardiac biomarkers to assess the risk of CA-AKI and major adverse kidney events in patients with CKD undergoing angiography.

Study design: A retrospective study.

Setting & participants: A subset of 922 participants from the Prevention of Serious Adverse Events following Angiography trial.

Predictors: Pre- and postangiography urinary tissue inhibitor of matrix metalloproteinase [TIMP]-2 and insulin growth factor binding protein [IGFBP]-7 were measured in 742 subjects, and plasma β natriuretic peptide (BNP) and high-sensitivity C-reactive protein (hs-CRP), and serum troponin (Tn) in 854 participants using samples obtained 1-2 hours before and 2-4 hours after angiography.

Outcomes: CA-AKI and major adverse kidney events.

Analytical approach: We fitted logistic regression to examine association and area under the receiver operating characteristic curves for risk prediction.

Results: There were no differences in postangiography urinary [TIMP-2]•[IGFBP7], plasma BNP, serum Tn, and hs-CRP concentrations among patients with and without CA-AKI and major adverse kidney events. However, higher pre- and postangiography median plasma BNP (pre: 200.0 vs 71.5, pg/mL, P = 0.05; post: 165.0 vs 81 pg/mL, P = 0.02); serum Tn (pre: 0.03 vs 0.01, ng/mL, P < 0.001; post, 0.04 vs 0.02, ng/mL, P = 0.01); and hs-CRP (pre: 9.55 vs 3.40 mg/L, P = 0.01; post: 9.90 vs 3.20 mg/L, P = 0.002) concentrations were associated with major adverse kidney events, although their discriminatory capacity was only modest (area under the receiver operating characteristic curves <0.7).

Limitations: Most participants were men.

Conclusions: Most mild CA-AKI cases are not associated with urinary cell cycle arrest biomarker elevation. Significant elevation in preangiography cardiac biomarkers may reflect patients with more significant cardiovascular disease that may predispose to poor long-term outcomes independent of CA-AKI status.

Keywords: Biomarker; angiography; cell cycle arrest; chronic kidney disease; contrast-associated acute kidney injury; major adverse kidney events.

© 2022 The Authors.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
Receiver operator characteristic curves of preangiography biomarkers for the risk prediction of major adverse kidney events.
Figure 2
Figure 2
Receiver operator characteristic curves of postangiography biomarkers for risk prediction of major adverse kidney events.

References

    1. Weisbord S.D., Gallagher M., Jneid H., et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med. 2018;378(7):603–614.
    1. Weisbord S.D., Mor M.K., Resnick A.L., et al. Prevention, incidence, and outcomes of contrast-induced acute kidney injury. Arch Intern Med. 2008;168(12):1325–1332.
    1. Weisbord S.D., Palevsky P.M., Kaufman J.S., et al. Contrast-associated acute kidney injury and serious adverse outcomes following angiography. J Am Coll Cardiol. 2020;75(11):1311–1320.
    1. Watabe H., Sato A., Hoshi T., et al. Association of contrast-induced acute kidney injury with long-term cardiovascular events in acute coronary syndrome patients with chronic kidney disease undergoing emergent percutaneous coronary intervention. Int J Cardiol. 2014;174(1):57–63.
    1. Liu C., Mor M.K., Palevsky P.M., et al. Postangiography increases in serum creatinine and biomarkers of injury and repair. Clin J Am Soc Nephrol. 2020;15(9):1240–1250.
    1. Parikh C.R., Liu C., Mor M.K., et al. Kidney biomarkers of injury and repair as predictors of contrast-associated AKI: a substudy of the PRESERVE trial. Am J Kidney Dis. 2020;75(2):187–194.
    1. Kashani K., Al-Khafaji A., Ardiles T., et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17(1):R25.
    1. Vijayan A., Faubel S., Askenazi D.J., et al. Clinical use of the urine biomarker [TIMP-2] × [IGFBP7] for acute kidney injury risk assessment. Am J Kidney Dis. 2016;68(1):19–28.
    1. Bihorac A., Chawla L.S., Shaw A.D., et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am J Respir Crit Care Med. 2014;189(8):932–939.
    1. Koyner J.L., Shaw A.D., Chawla L.S., et al. Tissue inhibitor metalloproteinase-2 (TIMP-2)IGF-binding protein-7 (IGFBP7) levels are associated with adverse long-term outcomes in patients with AKI. J Am Soc Nephrol. 2015;26(7):1747–1754.
    1. Heung M., Ortega L.M., Chawla L.S., et al. Common chronic conditions do not affect performance of cell cycle arrest biomarkers for risk stratification of acute kidney injury. Nephrol Dial Transplant. 2016;31(10):1633–1640.
    1. Chindarkar N.S., Chawla L.S., Straseski J.A., et al. Demographic data for urinary acute kidney injury (AKI) marker [IGFBP7].[TIMP2] reference range determinations. Data Brief. 2015;5:888–892.
    1. Gao F., Zhou Y.J., Zhu X., Wang Z.J., Yang S.W., Shen H. C-reactive protein and the risk of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. Am J Nephrol. 2011;34(3):203–210.
    1. Guerchicoff A., Stone G.W., Mehran R., et al. Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute ST-segment elevation myocardial infarction: results of the HORIZONS-AMI trial. Catheter Cardiovasc Interv. 2015;85(3):335–342.
    1. Jarai R., Dangas G., Huber K., et al. B-type natriuretic peptide and risk of contrast-induced acute kidney injury in acute ST-segment-elevation myocardial infarction: a substudy from the HORIZONS-AMI trial. Circ Cardiovasc Interv. 2012;5(6):813–820.
    1. Weisbord S.D., Gallagher M., Kaufman J., et al. Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. Clin J Am Soc Nephrol. 2013;8(9):1618–1631.
    1. Kidney Disease Improving Global Outcomes (KDIGO) work group: clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.
    1. Emlet D.R., Pastor-Soler N., Marciszyn A., et al. Insulin-like growth factor binding protein 7 and tissue inhibitor of metalloproteinases-2: differential expression and secretion in human kidney tubule cells. Am J Physiol Renal Physiol. 2017;312(2):F284–F296.
    1. Johnson A.C.M., Zager R.A. Mechanisms underlying increased TIMP2 and IGFBP7 urinary excretion in experimental AKI. J Am Soc Nephrol. 2018;29(8):2157–2167.
    1. Guzzi L.M., Bergler T., Binnall B., et al. Clinical use of [TIMP-2]∗[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel. Crit Care. 2019;23(1):225.
    1. Rothman K.J. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43–46.
    1. Rouve E., Lakhal K., Salmon Gandonniere C., Jouan Y., Bodet-Contentin L., Ehrmann S. Lack of impact of iodinated contrast media on kidney cell-cycle arrest biomarkers in critically ill patients. BMC Nephrol. 2018;19(1):308.
    1. Ostermann M., McCullough P.A., Forni L.G., et al. Kinetics of urinary cell cycle arrest markers for acute kidney injury following exposure to potential renal insults. Crit Care Med. 2018;46(3):375–383.
    1. Fox C.S., Muntner P., Chen A.Y., et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010;121(3):357–365.
    1. Szummer K., Lundman P., Jacobson S.H., et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med. 2010;268(1):40–49.
    1. Lau J.K., Anastasius M.O., Hyun K.K., et al. Evidence-based care in a population with chronic kidney disease and acute coronary syndrome. Findings from the Australian Cooperative National Registry of acute coronary care, guideline adherence and clinical events (CONCORDANCE) Am Heart J. 2015;170(3):566–572.e561.
    1. Medi C., Chew D.P., Amerena J., et al. An invasive management strategy is associated with improved outcomes in high-risk acute coronary syndromes in patients with chronic kidney disease. Intern Med J. 2011;41(10):743–750.
    1. Cashion W., Weisbord S.D. Radiographic contrast media and the kidney. Clin J Am Soc Nephrol. 2022;17(8):1234–1242.
    1. Rhee J.W., Wiviott S.D., Scirica B.M., et al. Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome. Clin Cardiol. 2014;37(6):350–356.
    1. Saad M., Karam B., Faddoul G., et al. Is kidney function affecting the management of myocardial infarction? A retrospective cohort study in patients with normal kidney function, chronic kidney disease stage III-V, and ESRD. Int J Nephrol Renovasc Dis. 2016;9:5–10.
    1. Chertow G.M., Normand S.L., McNeil B.J. “Renalism”: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J Am Soc Nephrol. 2004;15(9):2462–2468.
    1. Bhatt D.L., Roe M.T., Peterson E.D., et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004;292(17):2096–2104.
    1. Charytan D.M., Setoguchi S., Solomon D.H., Avorn J., Winkelmayer W.C. Clinical presentation of myocardial infarction contributes to lower use of coronary angiography in patients with chronic kidney disease. Kidney Int. 2007;71(9):938–945.
    1. Meersch M., Schmidt C., Van Aken H., et al. Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery. PLoS One. 2014;9(3)

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться